An Innovative Canadian Pharmaceutical Company

Revenue Projected at $150,000,000 by 2025

Valeo Pharma Inc. Profile



Valeo Pharma: A Successful, Revenue-Generating, Small-Cap Canadian Pharmaceutical Company 

Record revenues in 2021 of $13.6 million , up 81% over 2020 and Annual Gross Margins for 2021, $4 Million , up 186% over 2020 


What Makes Valeo Pharma Such An Interesting Pharmaceutical Company?

  • Redesca®, Enerzair® Breezhaler® and Atectura® Breezhaler®, three transformational products launched during 2021, will help accelerate revenues and margins in 2022
  • Public reimbursement secured in most provinces in Canada for Redesca, Enerzair Breezhaler and Atectura Breezhaler and all major private insurers
  • 9 products currently marketed ($40M. estimated peak sales / year)
  • 7 additional products in pipeline ($45M. estimated peak sales / year)
  • In-license business model, no development or clinical risk
  • Hesperco™ Capsules at the Core of Montreal Heart Institute's Hesperidin Coronavirus Clinical Trial
  • Completion of new corporate structure to allow for significant growth over the coming years and enable accelerated growth of commercial activities
  • $43 million raised in financings throughout 2021 and subsequent to year-end


Commercial Products



What Exactly Does Valeo Pharma Do?

  • Acquires Canadian rights to commercial stage, innovative and proprietary drugs
  • Commercializes innovative prescription products in Canada
  • Focused on Neurodegenerative Diseases,  Oncology and Hospital Specialty Products
  • Internally manages portfolio through all stages of commercialization


Here’s just a few products already approved:


Launch: Q1-2021

Status: Approved by Health Canada December 2020

Indication: Injectable blood thinner

Market size:  $200M

Received positive recommendation for public reimbursement in Quebec

To be covered under Ontario Public Drug Benefit program

Peak sales estimate $30 - $40M, sales margin 55 - 60%


Launch: Launched in Q4 -2020

Status: Approved by Health Canada

What is it: Anti-Oxidant - Immune system support

How’s it sold: Retail, Online (,

Market Size: $500M

  • Available in approximately 300 stores under the Loblaws banners
  • Clinical study yields encouraging results that hesperidin may help reduce COVID-19 associated symptoms





Launch: Q3 2019

Status: Received positive recommendation for public reimbursement in Quebec

Use: Parkinson's disease, 1st treatment launched in Canada since 2006

Patient base: 100,000 in Canada 2nd chronic neurodegenerative disorder after Alzheimer

Market Size: $20M

%Peak sales estimate $8M, sales margin 65-70 %



The Valeo ModelThe-Model

Company Forecast

  • All portfolio & pipeline products to be on the market by end 2022
  • Solid pipeline composed of “licensed” products
  • Peak Sales reached 2-4 years after market launch
  • From 1 product on the market to 12 in 4 years and more to come
  • Forecast excludes any new product licensing

Year Highlights Subsequent Events

  • In February 2022 , the Company announced that Enerzair Breezehaler and Atectura Breezhaler had been accepted for reimbursement by the Ontario Drug Benefit program, the Manitoba Pharmacare Program, the New Brunswick Drug plan, and the NIHB and VAC federal programs;
  • In January 2022 , the Company announced the availability of Hesperco in approximately 300 stores under the Loblaw's banners including Loblaws, Dominion, Zehrs, Fortinio's, Your Independent Grocer and Superstore. The Company also announced that the results of the Hesperidin Covid-19 clinical trial using Hesperco capsules had been submitted for publication. The study concluded that hesperidin could have beneficial effects and may help reduce certain Covid-19 symptoms.;
  • In December 2021 , the Company announced that Atectura Breezhaler and Enerzair Breezehaler were now reimbursed by the Quebec RAMQ, and by Nova Scotia Minister of Health;
  • In December 2021 , the Company repriced 1,336,700 warrants issued on April 27, 2021 as part of a bridge private placement of non-convertible debenture units. Consequently, the Company announced the amendment of the exercise price of the Bridge Warrants from $1.60 per Share to $1 ;
  • In December 2021 , the Company closed of a bought deal private placement of $15.0 million aggregate principal amount of 12.0% convertible unsecured debentures of the Company due December 31, 2024 at a price of $1,000 per Debenture. The Company also closed a concurrent $10.0 million private placement of convertible unsecured debentures issued on the same terms as those issuable pursuant to the Offering, resulting in gross proceed from the Offering and Concurrent Private Placement of $25.0 million to the Company. The Company issued a total of 25,000 Debentures accruing interest at the rate of 12% per annum payable quarterly beginning on March 31, 2022 . ;
  • In November 2021 , the Company successfully entered into a Product Listing Agreement with Quebec Minister of Health, for the listing and public reimbursement of Redesca and Redesca HP on the Quebec RAMQ list of medications, effective November 10, 2021 ; and
  • In November 2021 , the Company successfully entered into a Product Listing Agreement with Alberta Minister of Health, for the listing and public reimbursement of Enerzair Breezhaler and Atectura Breezhaler on the Alberta Drug Benefit list effective November 1, 2021 .


Last changed at 12-May-2022 11:43AM by AGORACOM-KE